Healthcare provider profile · identity verified

April Birkmire, NP-C

Nurse Practitioner · CLEVELAND, OH · NPI 1558028837

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	600	180
Amlodipine Besylate	Amlodipine Besylate	332	101
Gabapentin	Gabapentin	275	64
Lisinopril	Lisinopril	267	78
Metformin Hcl	Metformin Hcl	192	60
Omeprazole	Omeprazole	184	57
Albuterol Sulfate Hfa	Albuterol Sulfate	178	65
Telmisartan	Telmisartan	168	59
Rosuvastatin Calcium	Rosuvastatin Calcium	166	62
Trulicity	Dulaglutide	160	30
Metoprolol Succinate	Metoprolol Succinate	133	49
Tamsulosin Hcl	Tamsulosin Hcl	126	41
Levothyroxine Sodium	Levothyroxine Sodium	111	29
Famotidine	Famotidine	110	39
Losartan Potassium	Losartan Potassium	107	34
Ozempic	Semaglutide	106	24
Pantoprazole Sodium	Pantoprazole Sodium	106	33
Prednisone	Prednisone	105	72
Ketoconazole	Ketoconazole	101	54
Trazodone Hcl	Trazodone Hcl	101	37
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	100	24
Jardiance	Empagliflozin	99	27
Hydrochlorothiazide	Hydrochlorothiazide	97	30
Metformin Hcl Er	Metformin Hcl	95	34
Furosemide	Furosemide	87	31
Sertraline Hcl	Sertraline Hcl	82	22
Diclofenac Sodium	Diclofenac Sodium	76	35
Ezetimibe	Ezetimibe	75	22
Fluticasone Propionate	Fluticasone Propionate	74	33
Duloxetine Hcl	Duloxetine Hcl	73	22
Glipizide	Glipizide	69	25
Meloxicam	Meloxicam	67	25
Pregabalin	Pregabalin	66	suppressed
Montelukast Sodium	Montelukast Sodium	64	16
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	60	24
Tizanidine Hcl	Tizanidine Hcl	59	37
Chlorthalidone	Chlorthalidone	57	16
Simvastatin	Simvastatin	57	18
Citalopram Hbr	Citalopram Hydrobromide	55	12
Metoprolol Tartrate	Metoprolol Tartrate	54	15
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	52	17
Potassium Chloride	Potassium Chloride	50	16
Hydroxyzine Hcl	Hydroxyzine Hcl	49	23
Meclizine Hcl	Meclizine Hcl	49	25
Carvedilol	Carvedilol	48	16
Pravastatin Sodium	Pravastatin Sodium	47	suppressed
Symbicort	Budesonide/Formoterol Fumarate	47	17
Spiriva Respimat	Tiotropium Bromide	46	13
Triamcinolone Acetonide	Triamcinolone Acetonide	45	21
Eliquis	Apixaban	41	11
Alendronate Sodium	Alendronate Sodium	40	15
Finasteride	Finasteride	38	13
Januvia	Sitagliptin Phosphate	38	17
Allopurinol	Allopurinol	34	suppressed
Atenolol	Atenolol	34	suppressed
Clopidogrel	Clopidogrel Bisulfate	33	14
Mirtazapine	Mirtazapine	32	13
Spironolactone	Spironolactone	32	11
Pioglitazone Hcl	Pioglitazone Hcl	31	suppressed
Glipizide Er	Glipizide	30	suppressed
Topiramate	Topiramate	30	suppressed
Azithromycin	Azithromycin	29	25
Hydralazine Hcl	Hydralazine Hcl	29	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	29	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	28	suppressed
Ibuprofen	Ibuprofen	28	suppressed
Buspirone Hcl	Buspirone Hcl	27	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	27	suppressed
Glimepiride	Glimepiride	26	suppressed
Clonidine Hcl	Clonidine Hcl	25	suppressed
Propranolol Hcl	Propranolol Hcl	25	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	24	suppressed
Lidocaine	Lidocaine	24	suppressed
Xarelto	Rivaroxaban	23	11
Cephalexin	Cephalexin	22	19
Alcohol Prep Pads	Alcohol Antiseptic Pads	21	13
Ropinirole Hcl	Ropinirole Hcl	21	suppressed
Alcohol Pads	Alcohol Antiseptic Pads	20	suppressed
Bupropion Xl	Bupropion Hcl	20	suppressed
Easy Touch Alcohol Prep Pads	Alcohol Antiseptic Pads	20	suppressed
Mounjaro	Tirzepatide	20	suppressed
Donepezil Hcl	Donepezil Hcl	19	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	19	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	19	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	19	suppressed
Repatha Sureclick	Evolocumab	19	suppressed
Sucralfate	Sucralfate	19	suppressed
Spiriva Handihaler	Tiotropium Bromide	18	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	17	suppressed
Ondansetron Odt	Ondansetron	17	14
Ventolin Hfa	Albuterol Sulfate	17	suppressed
Bupropion Hcl Sr	Bupropion Hcl	16	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	16	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	15	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	15	suppressed
Naproxen	Naproxen	15	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	14	14
Baclofen	Baclofen	14	suppressed
Dulera	Mometasone/Formoterol	14	suppressed
Farxiga	Dapagliflozin Propanediol	14	suppressed
Nifedipine Er	Nifedipine	14	suppressed
Nitroglycerin	Nitroglycerin	14	suppressed
Nystatin	Nystatin	14	suppressed
Sildenafil Citrate	Sildenafil Citrate	14	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	13	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	13	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	13	12
Breo Ellipta	Fluticasone/Vilanterol	12	suppressed
Desloratadine	Desloratadine	12	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	12	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	12	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	12	suppressed
Ammonium Lactate	Ammonium Lactate	11	suppressed
Entresto	Sacubitril/Valsartan	11	suppressed
Fluconazole	Fluconazole	11	suppressed
Torsemide	Torsemide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error